Diagnosis of Allergic Contact Dermatitis With the New Zealand Baseline Series.

IF 1.8 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2025-07-02 DOI:10.1111/ajd.14555

Aysha Wilson, Harriet Kennedy

{"title":"Diagnosis of Allergic Contact Dermatitis With the New Zealand Baseline Series.","authors":"Aysha Wilson, Harriet Kennedy","doi":"10.1111/ajd.14555","DOIUrl":null,"url":null,"abstract":"Background/objectives: The New Zealand Baseline Series (NZBS) was developed in 2021 to ensure local patch testing was relevant to the population of New Zealand (NZ). It consists of 30 Core allergens and 30 Extended allergens. The aim of this study was to assess performance of the NZBS in diagnosing allergic contact dermatitis (ACD).Methods: A retrospective review was performed of patients patch tested between February 2022 and December 2023, at a public tertiary dermatology clinic and at a private dermatology clinic in Auckland, NZ. Patient demographics and the positivity rate of each allergen were recorded. Performance of the NZBS in diagnosing ACD was categorised as full detection (all relevant allergens identified), partial detection (some, but not all, relevant allergens identified) and no detection (no relevant allergens identified).Results: In total, 209 patients were included in data analysis; 94 from the public clinic and 115 from the private clinic. In total, 105 patients (50%) were diagnosed with ACD with at least one relevant reaction on patch testing. Of those diagnosed with ACD, testing against the NZBS (60 allergens) had a full detection rate of 66%, partial detection in 21% and no detection in 13%.Conclusions: Patch testing with the NZBS has a good detection rate for diagnosing ACD. However, detection of all relevant allergens requires supplementation with additional series and patients' own products. Regular updates to the series are required to improve diagnostic value in the population. We suggest combining study results, literature review and expert consensus to identify emerging or missed allergens not currently captured by the NZBS.","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajd.14555","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/objectives: The New Zealand Baseline Series (NZBS) was developed in 2021 to ensure local patch testing was relevant to the population of New Zealand (NZ). It consists of 30 Core allergens and 30 Extended allergens. The aim of this study was to assess performance of the NZBS in diagnosing allergic contact dermatitis (ACD).

Methods: A retrospective review was performed of patients patch tested between February 2022 and December 2023, at a public tertiary dermatology clinic and at a private dermatology clinic in Auckland, NZ. Patient demographics and the positivity rate of each allergen were recorded. Performance of the NZBS in diagnosing ACD was categorised as full detection (all relevant allergens identified), partial detection (some, but not all, relevant allergens identified) and no detection (no relevant allergens identified).

Results: In total, 209 patients were included in data analysis; 94 from the public clinic and 115 from the private clinic. In total, 105 patients (50%) were diagnosed with ACD with at least one relevant reaction on patch testing. Of those diagnosed with ACD, testing against the NZBS (60 allergens) had a full detection rate of 66%, partial detection in 21% and no detection in 13%.

Conclusions: Patch testing with the NZBS has a good detection rate for diagnosing ACD. However, detection of all relevant allergens requires supplementation with additional series and patients' own products. Regular updates to the series are required to improve diagnostic value in the population. We suggest combining study results, literature review and expert consensus to identify emerging or missed allergens not currently captured by the NZBS.

查看原文本刊更多论文

新西兰基线系列诊断过敏性接触性皮炎。

背景/目标：新西兰基线系列（NZBS）于2021年制定，以确保当地贴片测试与新西兰（NZ）人口相关。它由30个核心过敏原和30个扩展过敏原组成。本研究的目的是评估NZBS在诊断过敏性接触性皮炎（ACD）中的表现。方法：对2022年2月至2023年12月期间在新西兰奥克兰一家公立三级皮肤科诊所和一家私立皮肤科诊所进行贴片测试的患者进行回顾性研究。记录患者人口统计数据及各过敏原阳性率。NZBS在诊断ACD方面的表现分为完全检测（识别出所有相关过敏原）、部分检测（识别出部分但不是全部相关过敏原）和未检测（未识别出相关过敏原）。结果：共纳入209例患者；94个来自公立诊所，115个来自私人诊所。总共有105名患者（50%）被诊断为ACD，在斑贴试验中至少有一种相关反应。在被诊断为ACD的患者中，针对NZBS（60种过敏原）的检测完全检出率为66%，部分检出率为21%，未检出率为13%。结论：NZBS贴片试验对ACD有较好的检出率。然而，检测所有相关的过敏原需要补充额外的系列和患者自己的产品。需要定期更新该系列，以提高对人群的诊断价值。我们建议结合研究结果、文献综述和专家共识来确定NZBS目前未捕获的新出现或遗漏的过敏原。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.